# US 2023/0414662 A1 · Methods of using tumor infiltrating lymphocytes in double-refractory melanoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0414662 A1
- Document ID: US20230414662A1
- Status: Published application
- Kind: A1
- Application number: 18/464,469
- Filed: 2023-09-11
- Published: 2023-12-28
- Earliest claimed: 2017-06-05
- Assignees: Iovance Biotherapeutics, Inc.
- Applicants: Iovance Biotherapeutics, Inc.
- Inventors: Maria FARDIS
- Web page: https://patentgrep.com/patent/US20230414662A1

## CPC

- C12N 5/0634: {Cells from the blood or the immune system}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/42: Cancer antigens
- A61P 35/04: specific for metastasis
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- G01N 33/575: for cancer
- A61K 35/00: Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/57: Skin; melanoma
- C12N 2501/04: Immunosuppressors, e.g. cyclosporin, tacrolimus
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2304: Interleukin-4 (IL-4)
- C12N 2501/2307: Interleukin-7 (IL-7)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/2321: Interleukin-21 (IL-21)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2502/30: tumour cells
- G01N 2333/522: Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed.

## Claims

### Claim 1

A method of treating double-refractory metastatic melanoma in a patient in need thereof, the method comprising administering a therapeutically effective population of tumor infiltrating lymphocytes (TILs) to the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the double-refractory metastatic melanoma is a cutaneous double-refractory metastatic melanoma.

### Claim 3 (depends on 1)

The method of claim 1, wherein the double-refractory metastatic melanoma is refractory to at least two prior systemic treatment courses, not including neo-adjuvant or adjuvant therapies.

### Claim 4 (depends on 1)

The method of claim 1, wherein the double-refractory metastatic melanoma is refractory to aldesleukin or a biosimilar thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the double-refractory metastatic melanoma is refractory to pembrolizumab or a biosimilar thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the double-refractory metastatic melanoma is refractory to nivolumab or a biosimilar thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the double-refractory metastatic melanoma is refractory to ipilimumab or a biosimilar thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the double-refractory metastatic melanoma is refractory to ipilimumab or a biosimilar thereof and pembrolizumab or a biosimilar thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the double-refractory metastatic melanoma is refractory to ipilimumab or a biosimilar thereof and nivolumab or a biosimilar thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein the double-refractory metastatic melanoma is refractory to a BRAF inhibitor.

### Claim 11 (depends on 1)

The method of claim 1, wherein the double-refractory metastatic melanoma is refractory to a PD-L1 inhibitor.

### Claim 12 (depends on 11)

The method of claim 11, wherein the PD-L1 inhibitor is selected from the group consisting of avelumab, atezolizumab, durvalumab, and biosimilars thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein the double-refractory metastatic melanoma is refractory to a combination of a PD-1 inhibitor and a CTLA-4 inhibitor.

### Claim 14 (depends on 13)

The method of claim 13, wherein the PD-1 inhibitor is nivolumab or a biosimilar thereof and the CTLA-4 inhibitor is selected from the group consisting of ipilumumab, tremelimumab, and biosimilars thereof.

### Claim 15 (depends on 1)

The method of claim 1, wherein the double-refractory metastatic melanoma is refractory to a combination of a BRAF inhibitor and a MEK inhibitor.

### Claim 16 (depends on 15)

The method of claim 15, wherein the BRAF inhibitor is dabrafenib or a pharmaceutically-acceptable salt thereof and the MEK inhibitor is trametinib or a pharmaceutically-acceptable salt or solvate thereof.

### Claim 17 (depends on 1)

The method of claim 1, wherein the metastatic melanoma is resistant to a PD-1 inhibitor or PD-L1 inhibitor.

### Claim 18 (depends on 17)

The method of claim 17, wherein the PD-1 or PD-L1 inhibitor is selected from the group consisting of nivolumab, pembrolizumab, avelumab, atezolizumab, durvalumab, and biosimilars thereof.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of claims 1-10, wherein the patient does not possess a BRAF mutation.

### Claim 20 (depends on 1)

The method of claim 1, wherein the patient has received at most 4 doses of nivolumab or a biosimilar thereof prior to receiving the therapeutically effective population of TILs.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of claims 1-12, wherein the patient has progressed or had no response to at least two prior systemic treatment courses.

### Claim 22

A method of treating double-refractory metastatic melanoma in a patient in need thereof, the method comprising:
(a) obtaining a first population of TILs from a tumor resected from the patient by processing a tumor sample obtained from the patient into multiple tumor fragments;
(b) adding the tumor fragments into a closed system;
(c) performing a first expansion by culturing the first population of TILs in a cell culture medium comprising IL-2, and optionally OKT-3, to produce a second population of TILs, wherein the first expansion is performed in a closed container providing a first gas-permeable surface area, wherein the first expansion is performed for about 3-14 days to obtain the second population of TILs, wherein the second population of TILs is at least 50-fold greater in number than the first population of TILs, and wherein the transition from step (b) to step (c) occurs without opening the system;
(d) performing a second expansion by supplementing the cell culture medium of the second population of TILs with additional IL-2, optionally OKT-3, and antigen presenting cells (APCs), to produce a third population of TILs, wherein the second expansion is performed for about 7-14 days to obtain the third population of TILs, wherein the third population of TILs is a therapeutic population of TILs, wherein the second expansion is performed in a closed container providing a second gas-permeable surface area, and wherein the transition from step (c) to step (d) occurs without opening the system;
(e) harvesting the therapeutic population of TILs obtained from step (d) to provide a harvested TIL population, wherein the transition from step (d) to step (e) occurs without opening the system;
(f) transferring the harvested TIL population from step (e) to an infusion bag, wherein the transfer from step (e) to (f) occurs without opening the system, and optionally cryopreserving the harvested TIL population and
(g) administering a therapeutically effective amount of the harvested TIL population to the patient with double-refractory metastatic melanoma.

### Claim 23 (depends on 20)

The method of claim 20, wherein the patient has been previously treated with a PD-1 inhibitor or a biosimilar thereof.

### Claim 24 (depends on 21)

The method of claim 21, wherein the PD-1 inhibitor is selected from the group consisting of nivolumab, pembrolizumab, and biosimilars thereof.

### Claim 25 (depends on 20)

The method of claim 20, wherein the patient has been previously treated with a PD-L1 inhibitor or a biosimilar thereof.

### Claim 26 (depends on 25)

The method of claim 25, wherein the PD-L1 inhibitor is selected from the group consisting of avelumab, atezolizumab, durvalumab, and biosimilars thereof.

### Claim 27 (depends on 23, 24)

The method of any one of claims 23-24, wherein the PD-1 inhibitor or a biosimilar thereof was co-administered with a CTLA-4 inhibitor or biosimilar thereof.

### Claim 28 (depends on 25, 26)

The method of any one of claims 25-26, wherein the PD-L1 inhibitor or a biosimilar thereof was co-administered with a CTLA-4 inhibitor or biosimilar thereof

### Claim 29 (depends on 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 22-28, wherein the patient has been previously treated with one additional prior line of systemic therapy.

### Claim 30 (depends on 29)

The method of claim 29, wherein the one additional prior line of systemic therapy is a BRAF inhibitor or a pharmaceutically-acceptable salt thereof

### Claim 31 (depends on 30)

The method of claim 30, wherein the BRAF inhibitor is selected from the group consisting of vemurafenib, dabrafenib, and pharmaceutically-acceptable salts thereof

### Claim 32 (depends on 29)

The method of claim 29, wherein the one additional prior line of systemic therapy is a MEK inhibitor or a pharmaceutically-acceptable salt or solvate thereof

### Claim 33 (depends on 32)

The method of claim 32, wherein the MEK inhibitor is selected from the group consisting of trametinib, cobimetinib, and pharmaceutically-acceptable salts or solvates thereof

### Claim 34 (depends on 29)

The method of claim 29, wherein the one additional prior line of systemic therapy is a combination of a BRAF inhibitor or a pharmaceutically-acceptable salt thereof and a MEK inhibitor or a pharmaceutically-acceptable salt or solvate thereof

### Claim 35 (depends on 34)

The method of claim 34, wherein the BRAF inhibitor is selected from the group consisting of vemurafenib, dabrafenib, and pharmaceutically-acceptable salts thereof, and the MEK inhibitor is selected from the group consisting of trametinib, cobimetinib, and pharmaceutically-acceptable salts or solvates thereof

### Claim 36 (depends on 29)

The method of claim 29, wherein the one additional prior line of systemic therapy is a CTLA-4 inhibitor or a biosimilar thereof.

### Claim 37 (depends on 36)

The method of claim 36, wherein the CTLA-4 inhibitor is selected from the group consisting of ipilumumab, tremelimumab, and biosimilars thereof

### Claim 38 (depends on 29)

The method of claim 29, wherein the one additional prior line of systemic therapy is chemotherapeutic regimen.

### Claim 39 (depends on 38)

The method of claim 38, wherein the chemotherapeutic regimen comprises dacarbazine or temozolimide.

### Claim 40 (depends on 22)

The method of claim 22, wherein the first expansion is performed over a period of about 11 days.

### Claim 41 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 22-40, wherein the IL-2 is present at an initial concentration of between 1000 IU/mL and 6000 IU/mL in the cell culture medium in the first expansion step (c).

### Claim 42 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 22-40, wherein in the second expansion step (d), the IL-2 is present at an initial concentration of between 1000 IU/mL and 6000 IU/mL and the OKT-3 antibody is present at an initial concentration of about 30 ng/mL.

### Claim 43 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 22-42, wherein the first expansion is performed using a gas permeable container.

### Claim 44 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 22-42, wherein the second expansion is performed using a gas permeable container.

### Claim 45 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 22-44, wherein the cell culture medium in the first expansion step (c) further comprises a cytokine selected from the group consisting of TL-4, TL-7, IL-15, IL-21, and combinations thereof.

### Claim 46 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 22-44, wherein the cell culture medium in the second expansion step (d) further comprises a cytokine selected from the group consisting of IL-4, IL-7, IL-15, IL-21, and combinations thereof.

### Claim 47 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 22-46, further comprising the step of treating the patient with a non-myeloablative lymphodepletion regimen prior to administering the TILs to the patient.

### Claim 48 (depends on 47)

The method of claim 47, wherein the non-myeloablative lymphodepletion regimen comprises the steps of administration of cyclophosphamide at a dose of 60 mg/m2/day for two days followed by administration of fludarabine at a dose of 25 mg/m2/day for five days.

### Claim 49 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 22-48, further comprising the step of treating the patient with an IL-2 regimen starting on the day after administration of the TILs to the patient.

### Claim 50 (depends on 49)

The method of claim 49, wherein the IL-2 regimen is a high-dose IL-2 regimen comprising 600,000 or 720,000 11 J/kg of aldesleukin, or a biosimilar or variant thereof, administered as a 15-minute bolus intravenous infusion every eight hours until tolerance.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method according to any one of claims 1-50, wherein the therapeutically effective population of TILs comprises from about 2.3×1010 to about 13.7×1010 TILs.
